{"id":351744,"date":"2010-02-23T00:20:31","date_gmt":"2010-02-23T05:20:31","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=64584"},"modified":"2010-02-23T00:20:31","modified_gmt":"2010-02-23T05:20:31","slug":"gilead-sciences-gets-fda-green-light-to-sell-cystic-fibrosis-drug","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/351744","title":{"rendered":"Gilead Sciences Gets FDA Green Light To Sell Cystic Fibrosis Drug"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/FDA\/\">FDA<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/cystic-fibrosis\/\">Cystic Fibrosis<\/a><\/div>\n<p>\t\t<a rel=\"attachment wp-att-4867\" href=\"http:\/\/www.xconomy.com\/seattle\/2008\/09\/15\/gileads-seattle-crew-awaits-fda-clearance-of-cystic-fibrosis-drug-catalyst-for-future-growth\/attachment\/gileadlogo-2\/\"><img loading=\"lazy\" decoding=\"async\" style=\"float:right;margin: 0px 0 5px 15px;\" class=\"alignnone size-thumbnail wp-image-4867\" title=\"gileadlogo\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/images\/2008\/09\/gileadlogo-180x66.jpg\" alt=\"gileadlogo\" width=\"180\" height=\"66\" \/><\/a><br \/>\n\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Gilead Sciences paid $365 million to acquire Seattle-based Corus Pharma in 2006, and now it finally can see a way of getting a return on that investment in the U.S. The world&#8217;s leading marketer of HIV medicines <a href=\"http:\/\/www.gilead.com\/pr_1393831\">said<\/a> late Monday that the FDA has given it clearance to start selling an inhalable antibiotic to U.S. patients with cystic fibrosis.<\/p>\n<p>Foster City, CA-based Gilead (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=GILD\">GILD<\/a>) said it is now approved to start selling aztreonam lysine (Cayston) to help treat a nasty bacterial infection in the lungs called P.aeruginosa. The drug received clearance in Europe and Canada last September.<\/p>\n<p>&#8220;All of us at Gilead extend our thanks to the investigators and to the people with cystic fibrosis who took part in the Cayston clinical trials,&#8221; said Norbert Bischofberger, Gilead&#8217;s chief scientific officer, in a statement. &#8220;We look forward to making Cayston available to the cystic fibrosis community as soon as possible.&#8221;<\/p>\n<p>The FDA approval of the new cystic fibrosis drug isn&#8217;t expected to be a big profit driver for Gilead, but it&#8217;s a big deal for the Seattle crew, because it was their baby. Gilead is looking to diversify away from its heavy reliance on HIV drugs, and as part of that, <a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/01\/13\/gilead-deepens-roots-in-seattle-seeks-long-term-payoff-from-lung-disease-research\/\">has invested $50 million in a new Seattle research center<\/a> with 150 employees concentrated on lung diseases. It&#8217;s also potentially meaningful for the 30,000 people in the U.S. who have cystic fibrosis, a genetic disease in which thick, sticky mucus builds up in the lungs, which can get infected, and which usually means patients don&#8217;t live to turn 40. The new drug is the first new antibiotic for cystic fibrosis patients in more than 10 years, Gilead said.<\/p>\n<p>Gilead didn&#8217;t say how much the drug will cost in its news release, and a spokeswoman didn&#8217;t immediate respond to a request for comment late Monday.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/02\/23\/gilead-sciences-gets-fda-green-light-to-sell-cystic-fibrosis-drug\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Gilead%20Sciences%20Gets%20FDA%20Green%20Light%20To%20Sell%20Cystic%20Fibrosis%20Drug%20http:\/\/xconomy.com\/?p=64584\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/02\/23\/gilead-sciences-gets-fda-green-light-to-sell-cystic-fibrosis-drug\/&#038;t=Gilead%20Sciences%20Gets%20FDA%20Green%20Light%20To%20Sell%20Cystic%20Fibrosis%20Drug\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/02\/23\/gilead-sciences-gets-fda-green-light-to-sell-cystic-fibrosis-drug\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Gilead+Sciences+Gets+FDA+Green+Light+To+Sell+Cystic+Fibrosis+Drug&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F02%2F23%2Fgilead-sciences-gets-fda-green-light-to-sell-cystic-fibrosis-drug%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=b0b6f78623653837f0fa7006483579a1&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=b0b6f78623653837f0fa7006483579a1&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/Zj3JF18ez29dmTOUIjOl-mv1TWc\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/Zj3JF18ez29dmTOUIjOl-mv1TWc\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/Zj3JF18ez29dmTOUIjOl-mv1TWc\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/Zj3JF18ez29dmTOUIjOl-mv1TWc\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/3I26J5kiLfM\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, FDA, Cystic Fibrosis Luke Timmerman wrote: Gilead Sciences paid $365 million to acquire Seattle-based Corus Pharma in 2006, and now it finally can see a way of getting a return on that investment in the U.S. The world&#8217;s leading marketer of HIV medicines said late Monday that the FDA has given it clearance to [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-351744","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/351744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=351744"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/351744\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=351744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=351744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=351744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}